Sep 2026
Circulating fibroblast growth factor 21 predicts adverse outcomes in patients with pre-heart failure and HFpEF.
It is demonstrated that circulating FGF21 acts as an independent predictor of recurrent heart failure and all-cause death in patients with HFpEF, and may serve as a promising auxiliary biomarker for risk stratification of patients with HFpEF in clinical practice.
Hui-Ying Li, Yu Bao, Hu-Nan Xiao et al.
· Pathology, Research and Prac... · 0 citations